Xiyang Wei1, Lei Zhao2, Ruizhe Ren1, Fubo Ji1, Shuting Xue1, Jianjuan Zhang1, Zhaogang Liu2, Zhao Ma2, Xin W Wang3, Linda Wong4, Niya Liu1, Jiong Shi5, Xing Guo1, Stephanie Roessler6, Xin Zheng7, Junfang Ji1. 1. MOE Key Laboratory of Biosystems Homeostasis & Protection, Life Sciences Institute, Zhejiang University, Hangzhou, China. 2. Shandong Cancer Hospital and Institute, Shandong Cancer Hospital of Shandong First Medical University, Jinan, China. 3. Liver Cancer Program and Laboratory of Human Carcinogenesis, Cancer for Cancer Research, National Cancer Institute, Bethesda, MD. 4. University of Hawaii Cancer Center, Honolulu, HI. 5. Department of Pathology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China. 6. Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. 7. Ezkit LLC, Honolulu, HI.
Abstract
BACKGROUND AND AIMS: Transarterial chemoembolization (TACE) is a standard locoregional therapy for patients with hepatocellular carcinoma (HCC) patients with a variable overall response in efficacy. We aimed to identify key molecular signatures and related pathways leading to HCC resistance to TACE, with the hope of developing effective approaches in preselecting patients with survival benefit from TACE. APPROACH AND RESULTS: Four independent HCC cohorts with 680 patients were used. MicroRNA (miRNA) transcriptome analysis in patients with HCC revealed a 41-miRNA signature related to HCC recurrence after adjuvant TACE, and miR-125b was the top reduced miRNA in patients with HCC recurrence. Consistently, patients with HCC with low miR-125b expression in tumor had significantly shorter time to recurrence following adjuvant TACE in two independent cohorts. Loss of miR-125b in HCC noticeably activated the hypoxia inducible factor 1 alpha subunit (HIF1α)/pAKT loop in vitro and in vivo. miR-125b directly attenuated HIF1α translation through binding to HIF1A internal ribosome entry site region and targeting YB-1, and blocked an autocrine HIF1α/platelet-derived growth factor β (PDGFβ)/pAKT/HIF1α loop of HIF1α translation by targeting the PDGFβ receptor. The miR-125b-loss/HIF1α axis induced the expression of CD24 and erythropoietin (EPO) and enriched a TACE-resistant CD24-positive cancer stem cell population. Consistently, patients with high CD24 or EPO in HCC had poor prognosis following adjuvant TACE therapy. Additionally, in patients with HCC having TACE as their first-line therapy, high EPO in blood before TACE was also noticeably related to poor response to TACE. CONCLUSIONS: MiR-125b loss activated the HIF1α/pAKT loop, contributing to HCC resistance to TACE and the key nodes in this axis hold the potential in assisting patients with HCC to choose TACE therapy.
BACKGROUND AND AIMS: Transarterial chemoembolization (TACE) is a standard locoregional therapy for patients with hepatocellular carcinoma (HCC) patients with a variable overall response in efficacy. We aimed to identify key molecular signatures and related pathways leading to HCC resistance to TACE, with the hope of developing effective approaches in preselecting patients with survival benefit from TACE. APPROACH AND RESULTS: Four independent HCC cohorts with 680 patients were used. MicroRNA (miRNA) transcriptome analysis in patients with HCC revealed a 41-miRNA signature related to HCC recurrence after adjuvant TACE, and miR-125b was the top reduced miRNA in patients with HCC recurrence. Consistently, patients with HCC with low miR-125b expression in tumor had significantly shorter time to recurrence following adjuvant TACE in two independent cohorts. Loss of miR-125b in HCC noticeably activated the hypoxia inducible factor 1 alpha subunit (HIF1α)/pAKT loop in vitro and in vivo. miR-125b directly attenuated HIF1α translation through binding to HIF1A internal ribosome entry site region and targeting YB-1, and blocked an autocrine HIF1α/platelet-derived growth factor β (PDGFβ)/pAKT/HIF1α loop of HIF1α translation by targeting the PDGFβ receptor. The miR-125b-loss/HIF1α axis induced the expression of CD24 and erythropoietin (EPO) and enriched a TACE-resistant CD24-positive cancer stem cell population. Consistently, patients with high CD24 or EPO in HCC had poor prognosis following adjuvant TACE therapy. Additionally, in patients with HCC having TACE as their first-line therapy, high EPO in blood before TACE was also noticeably related to poor response to TACE. CONCLUSIONS: MiR-125b loss activated the HIF1α/pAKT loop, contributing to HCC resistance to TACE and the key nodes in this axis hold the potential in assisting patients with HCC to choose TACE therapy.
Authors: Jennifer Cable; Duanqing Pei; Lola M Reid; Xin Wei Wang; Sonam Bhatia; Panagiotis Karras; Jan Joseph Melenhorst; Markus Grompe; Justin D Lathia; Erwei Song; Calvin J Kuo; Ning Zhang; Richard M White; Stephanie Ky Ma; Lichun Ma; Y Rebecca Chin; Michael M Shen; Irene Oi Lin Ng; Klaus H Kaestner; Lei Zhou; Shaheen Sikandar; Clemens A Schmitt; Wei Guo; Carmen Chak-Lui Wong; Junfang Ji; Dean G Tang; Anna Dubrovska; Chunzhang Yang; Wolf R Wiedemeyer; Irving L Weissman Journal: Ann N Y Acad Sci Date: 2021-11-30 Impact factor: 6.499
Authors: Li Sun; Mu Xu; Guoying Zhang; Lin Dong; Jie Wu; Chenchen Wei; Kexin Xu; Lu Zhang Journal: Int J Genomics Date: 2021-12-27 Impact factor: 2.326
Authors: Alessandro Marco Bozzato; Paola Martingano; Roberta Antea Pozzi Mucelli; Marco Francesco Maria Cavallaro; Matteo Cesarotto; Cristina Marcello; Claudio Tiribelli; Devis Pascut; Riccardo Pizzolato; Fabio Pozzi Mucelli; Mauro Giuffrè; Lory Saveria Crocè; Maria Assunta Cova Journal: Diagnostics (Basel) Date: 2022-02-01